News

Four More Projects Awarded in COVID-19 Call

At the end of March, Health~Holland set up a call for COVID-19 related research proposals. In May we announced that in only one month four projects were awarded by the Health~Holland board. One week later, three more projects were awarded. Now, more good news is to follow; four more projects have been awarded and granted PPP Allowance to start their research.
Four More Projects Awarded in COVID-19 Call

Intravacc and EpiVax Team Up in Development of COVID-19 Emerging Vaccine

Intravacc, one of the world’s leading translational research and development vaccine institutes and EpiVax, a biotechnology company, announce that they have entered into a collaboration agreement to further progress an novel vaccine against COVID-19, based on Intravacc’s proprietary Outer Membrane Vesicles (OMV) technology platform.
Intravacc and EpiVax Team Up in Development of COVID-19 Emerging Vaccine

Key Stakeholders from Massachusetts and The Netherlands Discuss Lessons Learned from COVID-19

On Monday the 8th of June, key stakeholders from Massachusetts and the Netherlands will come together in a virtual session to discuss about the developments in both life sciences ecosystems in the light of the COVID-19 pandemic outbreak, and how international collaboration, now and in the future, could contribute to solutions.
Key Stakeholders from Massachusetts and The Netherlands Discuss Lessons Learned from COVID-19

New IMDI Newsletter Is Out Now

The new IMDI newsletter, June edition is out now. Read the publication of IMDI results of projects that received funding in 2014 and more!
New IMDI Newsletter Is Out Now

Mymetics Reports Successful Preclinical Study Results with Cop-Virosomes as Second-Generation Allergy Immunotherapy

Mymetics Corporation announced that Stallergenes Greer and Anergis, reported the results of a joint research study evaluating the effects of the second generation Contiguous Overlapping Peptides (COP) allergen immunotherapy in a therapeutic model of birch allergy, with the aim of shortening the AIT administration schemes.
Mymetics Reports Successful Preclinical Study Results with Cop-Virosomes as Second-Generation Allergy Immunotherapy

GSK Announces Intention to Produce 1 Billion doses of Pandemic Vaccine Adjuvant in 2021

GSK confirmed its intention to manufacture 1 billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted COVID-19 vaccine candidates.
GSK Announces Intention to Produce 1 Billion doses of Pandemic Vaccine Adjuvant in 2021

Core Life Analytics Closes €1M Series A Deal

The Netherlands-based data analytics company, Core Life Analytics, has closed a €1m Series A financing round. The investor team is composed of BOM Brabant Ventures, Utrecht Holdings and TechFund One.
Core Life Analytics Closes €1M Series A Deal

LUMC Constructs the Largest Stem Cell Facility for The Netherlands and Beyond

Leiden University Medical Center (LUMC) will start this year with the construction of the largest non-profit stem cell and gene therapy facility in the Netherlands, and one of the largest facilities in Europe. In the ‘NECSTGEN’ facility, the Netherlands Centre for the Clinical advancement of Stem Cell and Gene Therapies, research will be conducted in the field of regenerative medicine.
LUMC Constructs the Largest Stem Cell Facility for The Netherlands and Beyond

Organon Returns to The Netherlands

De bedrijfsnaam Organon keert terug in Nederland. Dat is het resultaat van overleg tussen de MSD-directie in Nederland en de Landelijke Ondernemingsraad die hierover advies moest uitbrengen. Vanuit de ondernemingsraad is er groen licht voor uitvoering en vervolgstappen in Nederland.
Organon Returns to The Netherlands

BOM Invests in Haermonics for Better Care After Open Heart Surgery

Haermonics, een spin-off van Amsterdam UMC, heeft de effectiviteit en veiligheid bewezen van het spoelen van het hartzakje na een openhartoperatie. Een experimentele opstelling zorgde voor significant minder bloedingsgerelateerde complicaties.
BOM Invests in Haermonics for Better Care After Open Heart Surgery